Skip to main content

Lian Brian's Form 4 filing

Viking Therapeutics, Inc. (VKTX) · filed Jan 31, 2024

Accession no.
0001209191-24-002512
Filed
Jan 31, 2024
Trade date
Jan 31, 2024
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.10M. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lian BrianCIK 0001614578Director, Officer (President & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 31, 2024Common Stock, par value $0.00001 per shareMOption exerciseAcquired+85,000$1.23+$104,5502,349,882Direct
Jan 31, 2024Common Stock, par value $0.00001 per shareSSaleDisposed−40,000$24.45−$978,0002,309,882Direct
Jan 31, 2024Common Stock, par value $0.00001 per shareSSaleDisposed−45,000$24.95−$1,122,7502,264,882Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jan 31, 2024Common StockMOption exerciseDisposed−85,000$0.00$014,148Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)